Key result
Low-dose rivaroxaban did not reduce cardiovascular events and increased major bleeding compared to placebo in patients with advanced CKD and high CV risk.
Why the study?
Does low-dose rivaroxaban reduce cardiovascular events in patients with advanced CKD and high cardiovascular risk?
Does low-dose rivaroxaban reduce cardiovascular events in patients with advanced CKD and high cardiovascular risk?
In patients with advanced CKD and high cardiovascular risk, low-dose rivaroxaban does not provide cardiovascular benefit and increases the risk of major bleeding.
Low-dose rivaroxaban should be avoided in advanced CKD with high CV risk; leaves open safer antithrombotic options for this population.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Mouawad et al. (2026) studied this question. Low-dose rivaroxaban did not reduce cardiovascular events and increased major bleeding compared to placebo in patients with advanced CKD and high CV risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: